Profil Kadar Homosistein Serum pada Pasien Vitiligo di RSUP H. Adam Malik Medan
51
DAFTAR PUSTAKA
1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A
comprehensive overview part I. Introduction, epidemiology, quality of
life, diagnosis, differential diagnosis, associations, histopathology,
etiology, and work-up. J Am Acad Dermatol [Internet] 2011[ cited 2015
Oct 22];65:473-91. Available from:http://www.ncbi.nlm.nih.gov/
pubmed/ 21839315.
2. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI,
Gilchrest BA, Paller AS, Leffel DJ, Wolff K,editors. Fitzpatrick's
dermatology in general medicine. 8 th ed. New York: The MCGrawHill companies. 2012. p. 1308-24.
3. Ezzedine K, Lifn HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et
al.Revised classification/nomenclature of vitiligo and related issues: the
vitiligo global issues consensus conference . Pigment Cell Melanoma
Res. 2012 May; 25(3): El-13. doi:10.1111/j.l755-148X.2012.00997.x.
3. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the
published work. Journal of Dermatology. 2011;38:419-31. doi: 10.111
1/j.1346-8138.2010.01139.x.
5. Gawkrodger DJ, Omerod AD, Shaw L, Mauri-sole I, Whitton ME, Watts
MJ, et al.Guideline for the diagnosis and management of vitiligo. BJD.
2008; 159: 1051-76. doi: 10.1111/j.1365-2133.2008.08881.x.
6. Vrijman C, Homan MWL, Limpens J, Veen WVD, Wolkerstorfer AW,
Terwee CB, et al. Measurement properties of outcome measures for
vitiligo. Arch Dermatol [Internet]. 2012 [cited 2015 Oct 24]; 148(11):
1302-9.Available from:http://www.ncbi.nlm.nih.gov/pubmed/ 22986764.
7. Ping TW, KeE GB, lan TS, Kumarasinghe P. Clinical profile of vitiligo
in Singapore: an analysis over a 6-month period. Dermatology bulletin [
Internet]. 2007 [ cited 2015 Oct 26] ; September 18 (2): 19-23. Available
from: https://www.nsc.coin.sg/Professional-Education/Documents/NSCBulletin-PDF/vol-18-no-2-2007.pdf.
8. Jusuf NK, Meher C. Pola Kelainan Pigmentasi di Poliklinik Kulit dan
Kelamin Divisi Kosmetik RSUP H. Adam Malik Medan Tahun 20122015. Pertemuan Ilmiah Tahunan XV Ilmu Kesehatan Kulit dan Kelamin.
Padang, Indonesia.
9. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin
RSUP Dr. M Djamil Padang tahun 2001-2006. MDVI [Internet]. 2008
[cited 2015 Oct 26]; Januari 35 (1): 77. Available from:
http://www.perdoski.org /index.php /public /information /mdvi-detailcontent/77.
10. Spritz RA. Modern vitiligo genetics sheds new light on ancient disease. J
Dermatol. 2013 May; 40(5): 1-15. doi:10.1111/1346-8138.12147.
11. Karadag AS, Tutal E, Ertugrul DT, Akint KO, Bilgili SG. Serum
holotranscobalamine, vitamin B12, folic acid and homocysteine levels in
patients with vitiligo. Clin Exp Dermatol. 2011 April; 37: 62-4.
doi:10.1111/j. 1365-2230.2011.04142.x.
Universitas Sumatera Utara
52
12. Bolander-Gouaille C. Homocysteine, the new marker of disease risk-an
overview. Business briefing: European pharmacotherapy. 2005;2-8.
doi:10.1.1.199.9952.
13. Selhub J. Homocysteine metabolism. Annu. Rev Nutr. 1999; 19:217-46.
doi:0199-9885/99/0715-0217$08.00.
14. Clarke
S,
Banfield
K.
S-Adenosylmethionine-dependent
methyltransferases. In: Carmel R, Jacobsen DW, editors. Homocysteine
in health and disease. Cambridge. Cambridge university press; 2001.p.
63-78
15. Shaker OG, El-Tahlawi SMR. Is there a relationship between
homocysteine and vitiligo? A pilot study. BJD. 2008; 159: 720-4. doi:
10.1111/J.1365-2133.2008.08712.X.
16. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with
vitamin B12 and folic acid and the importance of sun exposure. Acta
Derm Venereol. 1997; 77:460-2. doi:0001-5555.
17. Don P, iuga A, Dacko A, Hardick K. Treatment of vitiligo with
broadband ultraviolet B and vitamins. Int J Dermatol [Internet]. 2006 [
cited 2015 Oct 23] ; 45:63-5. Available from: http://www.ncbi. nlm.nih.
gov/pubmed/ 16426381.
18. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and
homocysteine levels in Indian vitiligo patients. EDOJ [ Internet]. 2012
June [ cited 2015 Oct 23]; 8(1):1-7. Available from: http :// www. edoj.
org.eg/vol008/0801/002/01.htm.
19. Balci DD, Yunden Z, Yenin JZ, Okumus N. Serum homocysteine, folic
acid and vitamin B12 levels in vitiligo. EJD. 2009 Jul-Aug; 19 (4): 3823. doi:10.1684/ejd.2009.0671.
20. Millington G W. M, Levell N J. Vitiligo: the historical curse of
depigmentation. International Journal of Dermatology. 2007;46: 990-5.
doi: 10.1111/j. 1365-4632.2007.03195.x.
21. Rahman MH, Amin MZ, Rahman M, Satter MA. A demographic study
on vitiligo (sheti) in Bangladesh. Int J Res Med Sci. 2013; 1(2):123-8.
doi: 10.5455/2320-6012.ijrms20130517.
22. Puri N, Phil M, Mojamdar M, Ramaiah A. In vitro growth characteristics
of melanocytes obtained from adult normal and vitiligo subjects.The
journal of investigative dermatology. 1987; 88(4): 434-8. doi: 0022202X/87/$03.50.
23. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide
insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132:
268-73. doi: 10.1038/jid.2011.321.
24. Baum S, Barzilai A, Trau H. Vitiligo. In : Shoenfeld Y, Cervera R,
Gershwin ME, editors. Diagnostic criteria in autoimmune diseases.
Humana press [Internet]. 2008 [cited 2015 Oct 01].p. 353-8. Available
from: http://link.springer.com/ book/ 10.1007%2F978-l-60327-285-8
Universitas Sumatera Utara
53
25. Bowcock AM, Fernandez-Vina M. Targeting skin: vitiligo and autoimm
unity. J Invest Dermatol. 2012; 132: 13-5. doi:10.103S /jid.201 1.353.
26. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N.
Thl7 cells and activated dendritic cells are increased in vitiligo lesions.
PLoS One. 2011 April; 6(4): 1-11. doi: 10.1371/journal.pone.0018907
27. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an
aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21:
865-876.doi: 10.1111/J.1468-3083.2007.02228.X.
28. Kemp EH, Emhemad S, Gawkrodger DJ, Weetman AP. Autoimmune
disorders-pathogenic aspects. Chapter 14. p. 255-78.
29. Haider N, Islam MS, Al-Maraf A, Shohag MH, Ali R, Rahman GKMM,
Hasnat A. Oxidative stress and antioxidant status in vitiligo patients.
Dhaka Univ J Pharm Sci. 2010 Dec; 9(2): 103-8. doi:
10.3329/dujps.v9i2.7894.
30. Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of
pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot
study. J Res Pharm Pract 2012; 1:77-80. doi: 10.4 103/2279-042X.
108375.
31. Shin JW, Nam KM, Choi HR, Huh SY, Kirn SW, Youn SW, et al.
Erythrocyte malondialdehyde and glutathione levels in vitiligo patients.
Ann Dermatol. 2010; 22(3): 279-83. doi: 10.5021/ad.2010.22.3.279.
32. Amin MZ, Rahman MH, Satter MA. Study of some biochemical
parameters of vitiligo patients in Bangladesh. Bangladesh J Sci Ind Res [
Internet]. 2012 [ cited 2015 Oct 20]; 47(2): 173-86. Available from: .
http://www.banglajol.info/index.php/BJSIR /article/view II 1449.
33. Esmaeili B, Rezaee SAR, Layegh P, Afshari JT, Dye P, Karimiani EG,
et al . Expression of IL-17 and COX2 gene in peripheral blood
leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol
[Internet]. 2011 [cited 2015 Oct 1]; 10(2):81-9. Available from:
http://www.sid.ir /en/VEWSSID/J_pdf/943201 10202.pdf.
34. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci.
2011; 120: 99-120.doi: 10.1042/CS20090603.
35. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of
oxidant-antioxidant status in blood and tissue in vitiligo patients. EDOJ
[Internet].2010 [cited 2015 Oct 1] ; 6(2): 1-10. Available from:
http://www.edoj.org.eg/vol006/0602/002/paper.pdf.
36. Faria AR, Mira MT, Tarle RG, Castro CCS, Dellatore G. Vitiligo-part2
classification, histopathology and treatment. An Bras Dermatol.
2014;89(5):784-90.doi: 10.1590/abdl806-4841.20142717.
37. Taieb A, Alomar A, Bohm M, Dell'Anna ML, PAse D, Eleftheriadou V,
et al. Guidelines for the management of vitiligo: the European
dermatology forum concencus. BJD. 2012 July; 168:5-19.
doi:10.1111/j.l365-2133.2012.11197.x.
Universitas Sumatera Utara
54
38. Brazelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A,
Borroni G. Critical evaluation of the variants influencing the clinical
response of vitiligo: study of 60 cases treated with ultraviolet B narrow
band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74.
doi: 10.1111/j.1468-3083.2007.02278.x.
39. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, Cario^Andre M,
Gauthier Y. Segmental vitiligo as the possible expression of cutaneous
somatic mosaicism: implications for common non-segmental vitiligo.
Pigment Cell Melanoma Res. 2008; 21:646-52. doi: 10.1111/j. 1755148X.2008.00511.x.
40. Hann S, Chang J, Lee H, Kim S. The classification of segmental vitiligo
on the face. Yonsei Med J [Internet]. 2000 [ cited 2015 Oct 22]; 41(2):
209-12. Available from:http://www.ncbi.nlm.nih.gov/pubmed/10817021.
41. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol
Venereol Leprol [serial online] 2006 [cited 2015 Nov 10];72:315-21.
Available from: http://www.ijdvl. com/text.asp?2006/72/4/315/26722.
42. Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for
the evaluation of vitiligo. JEADV. 2012;1-9. doi: 10.1111/j. 14683083.2012.04505.x.
43.Taieb A, Picardo M. The definition and assessment of vitiligo: a
consensus report of the Vitiligo European Task Force. Pigment Cell
Res.2007; 20:27-35. doi: 10.1111/j.1600-0749.2006.00355.
44. Kawakami T, Hashimoto T. Disease severity indexes and treatment
evaluation criteria in vitiligo. Dermatol Res Pract. 2011; 1-3. doi:
10.1155 72011/750342.
45. Al-mutairi N, Nour-Eldin O. Vitiligo treatment update. GJDV [Internet].
2003 Oct [cited 2015 Oct 23] ;10 (2): 1-13. Available from: http://www.
gulfdermaj ournal. com/pdf/2003 -10/1 .pdf.
46. Bordere AC, Lambert J, Geel NV. Current and emerging therapy for the
management of vitiligo. Clin Cosmet Investig Dermatol [Internet].
2009[cited 2015 Oct 25] ; 2: 15-25. Available from: http://www. ncbi
.nlm. nih.gov/pmc/articles/PMC3047938/.
47. Felsten L, Alikhan A, Petronic-Rosic V. Vitiligo:A comprehensive
overview part II: Treatment options and approach to treatment. J Am
Acad Dermatol [Internet]. 2011[ cited 2015 Oct 22];65:493-514.
Available from: http://www .ncbi.nlm. nih.gov/pubmed/21839316.
48. Clarke R. Lowering blood homocysteine with folic acid base
supplements: meta-analysis of randomised trials. BMJ [Internet].
1998[cited 2015 Oct 2]; 894-8. Available from:
http://www.
ncbi.nlm.nih.gov/pmc/articles/PMC28491/pdt7894.pdf.
49. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid, levels and methylenetetrahtdrofolate reductase
(MTHFR) gene polymorphism in vitiligo. Dis Markers. 2012; 33:85-9.
doi: 10.3233/DMA-2012-0908..
Universitas Sumatera Utara
55
50. Andre's E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin
AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients.
CMAJ [Internet]. 2004 [cited 2015 Oct 1] ; 17(3): 251-9. Available
from:http://www.researchgate.net/profile/Frederic_Maloisel/publicatio
n/8421627_Vitamin_B12_(cobalamin)_deficiency_in_elderly_patients
/links/OOb49 52289e7cc6179000000.pdf.
51. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bj0rke-Monsen AL,
Schneede J. Riboflavin as a determinant of plasma total homocysteine:
effect modification by the rnethylenetetrahydrofolate reductase C677T
polymorphism. Clin Chem [ Internet]. 2000 [ cited 2015 Oct 25]; May
46 (8): 1065-71. Available from: http://www .clinchem .
org/content/46/8/1065. Long.
52. Ubbink JB, Vermaak WJH, Merwe AVD, Becker PJ. Vitamin B12,vitamin b-6, and folate nutritional status in men
withhyperhomocysteinemia. Am J Clin Nutr [Internet]. 1993 [ cited
2015 Oct23] ; 57: 47-53. Availabe from: http://ajcn. nutrition,
org/ content' /57/l/47.1ong.
53. Bailey LB, Gregory JF. Folate metabolism and requirements. J. Nutr
[Internet]. 1999 [cited 2015 Oct 27]; 129: 779-82. Available from:
http://jn.nutrition.org/content/129/4/779.full.pdf+html.
54. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine,
vitamin B12, and folic acid in vitiligo. Egypt J Dermatol Venerol
[Internet] 2014 [cited 2015 Nov 27];34:65-9. Available from:
http://www.ejdv.eg.net/text.asp?2014/34/l/65/137315.
55. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of
vitiligo vulgaris severity: A pilot study. J Am Acad Dermatbl. 2011.
64(2): 445-7. doi: 10.1016/j,jaad.2010.08.025.
56. Ghalamkarpour F Jafarian Z, Einollahi H, Younespour S.
Homocysteine: is it a biomarker for vitiligo? Journal of pigmentary
disorders. 2015; 2(4): 1-4. doi: 10.4172/2376-0427.1000172.
57. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid levels and methylenetetrahydrofolate reductase
(MTHFR) gene polymorphism in vitiligo. Disease markers. 2012; 33:
85-9. Doi: 10.3233/DMA-2012-0908.
58. Yu H, Chang K, Yu C, Li H, Wu M, Wu C,et al. Alterations in IL-6,
IL-8, GM-CSF, TNF-a, and IFNy release by peripheral mononuclear
cells in patients
with active vitiligo.
J invest Dermatol.
1997.108: 527-9. doi: 10.111 l/1523-1747.ep12289743.
59. Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei
N.The involvement of Smac/DIABLO, p53,NF-kB, and MAPK
pathways in apoptosis of keratinocytes from perilesional vitiligft skin:
protective effects of curcumin and capsaicin. Antioxidants & Redox
Signaling. 2010; 13(9): 1309-21. doi: 10.1089/ars.2009.2779.
60. Silverberg NB. The Epidemiology of Vitiligo. Curr Derm Rep. 2015
Januari; 4:36–43.doi: 10.1007/s13671-014-0098-6.
61. Lee H. Prevalence of Vitiligo and Associated Comorbidities in Korea.
Yonsei
Med
J.
2015
Mei;
56(3):
719-25.
doi:
10.3349/ymj.2015.56.3.719.
Universitas Sumatera Utara
56
62. Jha BN. Assessment of Prevalence of Clinical and Sociodemographic
Study of Vitiligo in Janaki Medical College, Nepal. 2016
Februari;ARJLS. 2(2):1 – 4. ISSN: 2455-3549.
63. Wang X, et al. Prevalence and Clinical Profile of Vitiligo in China: A
Community based Study in Six Cities. Acta Derm Venereol 2013; 93:
62–5. doi: 10.2340/00015555-1397.
64. Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS. Gender
Differences in Clinicoepidemiological Features of Vitiligo: A CrossSectional Analysis. ISRN Dermatology. 2014 Feb;1-6. doi:
10.1155/2014/186197.
65. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine
and vitiligo. The gulf journal of dermatology and venereology[Internet].
2014[ cited 2015 Nov 29] ; 21(2): 15-20. Availble from: https://www.
google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0ah
UKEwjzy8p1cnKAhVBBY4KHQnjB1EQFggrMAI&url=http%3A%2F
%2Fwww.gulfdermajournal.com%2Fpdf%2F201410%2F2.pdf&usg=AF
QjCNGXyvhhvl6trAe0SHRVAImXn0Yi1g&sig2=5MUvJNMVGIU_eS
1rBkBO7A&cad=rj
66. Koehler KM, Baum RG, Gary PJ, Allen RH, Stabler SP, Rimm EB.
Association of folate intake and serum homocysteine in elderly persons
according to vitamin supplementation and alcohol use. Am J Clin Nutr.
2001 March ; 73:628–37. PMID:11237942.
67. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum
levels of Vitamin B, folic acid, and homocysteine in vitiligo. Pigment Int
2015;2:76-80. doi: 10.4103/2349-5847.172777
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A
comprehensive overview part I. Introduction, epidemiology, quality of
life, diagnosis, differential diagnosis, associations, histopathology,
etiology, and work-up. J Am Acad Dermatol [Internet] 2011[ cited 2015
Oct 22];65:473-91. Available from:http://www.ncbi.nlm.nih.gov/
pubmed/ 21839315.
2. Birlea SA, Spritz RA, Noris DA. Vitiligo. In: Goldsmith LA, Katz SI,
Gilchrest BA, Paller AS, Leffel DJ, Wolff K,editors. Fitzpatrick's
dermatology in general medicine. 8 th ed. New York: The MCGrawHill companies. 2012. p. 1308-24.
3. Ezzedine K, Lifn HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et
al.Revised classification/nomenclature of vitiligo and related issues: the
vitiligo global issues consensus conference . Pigment Cell Melanoma
Res. 2012 May; 25(3): El-13. doi:10.1111/j.l755-148X.2012.00997.x.
3. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: A review of the
published work. Journal of Dermatology. 2011;38:419-31. doi: 10.111
1/j.1346-8138.2010.01139.x.
5. Gawkrodger DJ, Omerod AD, Shaw L, Mauri-sole I, Whitton ME, Watts
MJ, et al.Guideline for the diagnosis and management of vitiligo. BJD.
2008; 159: 1051-76. doi: 10.1111/j.1365-2133.2008.08881.x.
6. Vrijman C, Homan MWL, Limpens J, Veen WVD, Wolkerstorfer AW,
Terwee CB, et al. Measurement properties of outcome measures for
vitiligo. Arch Dermatol [Internet]. 2012 [cited 2015 Oct 24]; 148(11):
1302-9.Available from:http://www.ncbi.nlm.nih.gov/pubmed/ 22986764.
7. Ping TW, KeE GB, lan TS, Kumarasinghe P. Clinical profile of vitiligo
in Singapore: an analysis over a 6-month period. Dermatology bulletin [
Internet]. 2007 [ cited 2015 Oct 26] ; September 18 (2): 19-23. Available
from: https://www.nsc.coin.sg/Professional-Education/Documents/NSCBulletin-PDF/vol-18-no-2-2007.pdf.
8. Jusuf NK, Meher C. Pola Kelainan Pigmentasi di Poliklinik Kulit dan
Kelamin Divisi Kosmetik RSUP H. Adam Malik Medan Tahun 20122015. Pertemuan Ilmiah Tahunan XV Ilmu Kesehatan Kulit dan Kelamin.
Padang, Indonesia.
9. Rizal Y, Lestari S. Insidensi vitiligo di poliklinik kulit dan kelamin
RSUP Dr. M Djamil Padang tahun 2001-2006. MDVI [Internet]. 2008
[cited 2015 Oct 26]; Januari 35 (1): 77. Available from:
http://www.perdoski.org /index.php /public /information /mdvi-detailcontent/77.
10. Spritz RA. Modern vitiligo genetics sheds new light on ancient disease. J
Dermatol. 2013 May; 40(5): 1-15. doi:10.1111/1346-8138.12147.
11. Karadag AS, Tutal E, Ertugrul DT, Akint KO, Bilgili SG. Serum
holotranscobalamine, vitamin B12, folic acid and homocysteine levels in
patients with vitiligo. Clin Exp Dermatol. 2011 April; 37: 62-4.
doi:10.1111/j. 1365-2230.2011.04142.x.
Universitas Sumatera Utara
52
12. Bolander-Gouaille C. Homocysteine, the new marker of disease risk-an
overview. Business briefing: European pharmacotherapy. 2005;2-8.
doi:10.1.1.199.9952.
13. Selhub J. Homocysteine metabolism. Annu. Rev Nutr. 1999; 19:217-46.
doi:0199-9885/99/0715-0217$08.00.
14. Clarke
S,
Banfield
K.
S-Adenosylmethionine-dependent
methyltransferases. In: Carmel R, Jacobsen DW, editors. Homocysteine
in health and disease. Cambridge. Cambridge university press; 2001.p.
63-78
15. Shaker OG, El-Tahlawi SMR. Is there a relationship between
homocysteine and vitiligo? A pilot study. BJD. 2008; 159: 720-4. doi:
10.1111/J.1365-2133.2008.08712.X.
16. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with
vitamin B12 and folic acid and the importance of sun exposure. Acta
Derm Venereol. 1997; 77:460-2. doi:0001-5555.
17. Don P, iuga A, Dacko A, Hardick K. Treatment of vitiligo with
broadband ultraviolet B and vitamins. Int J Dermatol [Internet]. 2006 [
cited 2015 Oct 23] ; 45:63-5. Available from: http://www.ncbi. nlm.nih.
gov/pubmed/ 16426381.
18. Singh S, Singh U, Pandey SS. Serum folic acid, vitamin B12 and
homocysteine levels in Indian vitiligo patients. EDOJ [ Internet]. 2012
June [ cited 2015 Oct 23]; 8(1):1-7. Available from: http :// www. edoj.
org.eg/vol008/0801/002/01.htm.
19. Balci DD, Yunden Z, Yenin JZ, Okumus N. Serum homocysteine, folic
acid and vitamin B12 levels in vitiligo. EJD. 2009 Jul-Aug; 19 (4): 3823. doi:10.1684/ejd.2009.0671.
20. Millington G W. M, Levell N J. Vitiligo: the historical curse of
depigmentation. International Journal of Dermatology. 2007;46: 990-5.
doi: 10.1111/j. 1365-4632.2007.03195.x.
21. Rahman MH, Amin MZ, Rahman M, Satter MA. A demographic study
on vitiligo (sheti) in Bangladesh. Int J Res Med Sci. 2013; 1(2):123-8.
doi: 10.5455/2320-6012.ijrms20130517.
22. Puri N, Phil M, Mojamdar M, Ramaiah A. In vitro growth characteristics
of melanocytes obtained from adult normal and vitiligo subjects.The
journal of investigative dermatology. 1987; 88(4): 434-8. doi: 0022202X/87/$03.50.
23. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide
insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132:
268-73. doi: 10.1038/jid.2011.321.
24. Baum S, Barzilai A, Trau H. Vitiligo. In : Shoenfeld Y, Cervera R,
Gershwin ME, editors. Diagnostic criteria in autoimmune diseases.
Humana press [Internet]. 2008 [cited 2015 Oct 01].p. 353-8. Available
from: http://link.springer.com/ book/ 10.1007%2F978-l-60327-285-8
Universitas Sumatera Utara
53
25. Bowcock AM, Fernandez-Vina M. Targeting skin: vitiligo and autoimm
unity. J Invest Dermatol. 2012; 132: 13-5. doi:10.103S /jid.201 1.353.
26. Wang CQF, Cruz-Inigo AE, Fuentes-Duculan J, Moussai D, Gulati N.
Thl7 cells and activated dendritic cells are increased in vitiligo lesions.
PLoS One. 2011 April; 6(4): 1-11. doi: 10.1371/journal.pone.0018907
27. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an
aetiological factor in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21:
865-876.doi: 10.1111/J.1468-3083.2007.02228.X.
28. Kemp EH, Emhemad S, Gawkrodger DJ, Weetman AP. Autoimmune
disorders-pathogenic aspects. Chapter 14. p. 255-78.
29. Haider N, Islam MS, Al-Maraf A, Shohag MH, Ali R, Rahman GKMM,
Hasnat A. Oxidative stress and antioxidant status in vitiligo patients.
Dhaka Univ J Pharm Sci. 2010 Dec; 9(2): 103-8. doi:
10.3329/dujps.v9i2.7894.
30. Naini FF, Shooshtari AV, Ebrahimi B, Molaei R. The effect of
pseudocatalase/superoxide dismutase in the treatment of vitiligo: a pilot
study. J Res Pharm Pract 2012; 1:77-80. doi: 10.4 103/2279-042X.
108375.
31. Shin JW, Nam KM, Choi HR, Huh SY, Kirn SW, Youn SW, et al.
Erythrocyte malondialdehyde and glutathione levels in vitiligo patients.
Ann Dermatol. 2010; 22(3): 279-83. doi: 10.5021/ad.2010.22.3.279.
32. Amin MZ, Rahman MH, Satter MA. Study of some biochemical
parameters of vitiligo patients in Bangladesh. Bangladesh J Sci Ind Res [
Internet]. 2012 [ cited 2015 Oct 20]; 47(2): 173-86. Available from: .
http://www.banglajol.info/index.php/BJSIR /article/view II 1449.
33. Esmaeili B, Rezaee SAR, Layegh P, Afshari JT, Dye P, Karimiani EG,
et al . Expression of IL-17 and COX2 gene in peripheral blood
leukocytes of vitiligo patients. Iran J Allergy Asthma Immunol
[Internet]. 2011 [cited 2015 Oct 1]; 10(2):81-9. Available from:
http://www.sid.ir /en/VEWSSID/J_pdf/943201 10202.pdf.
34. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci.
2011; 120: 99-120.doi: 10.1042/CS20090603.
35. Kamel N, Sobhy N, Kamal H, Ismail M. A comparative study of
oxidant-antioxidant status in blood and tissue in vitiligo patients. EDOJ
[Internet].2010 [cited 2015 Oct 1] ; 6(2): 1-10. Available from:
http://www.edoj.org.eg/vol006/0602/002/paper.pdf.
36. Faria AR, Mira MT, Tarle RG, Castro CCS, Dellatore G. Vitiligo-part2
classification, histopathology and treatment. An Bras Dermatol.
2014;89(5):784-90.doi: 10.1590/abdl806-4841.20142717.
37. Taieb A, Alomar A, Bohm M, Dell'Anna ML, PAse D, Eleftheriadou V,
et al. Guidelines for the management of vitiligo: the European
dermatology forum concencus. BJD. 2012 July; 168:5-19.
doi:10.1111/j.l365-2133.2012.11197.x.
Universitas Sumatera Utara
54
38. Brazelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A,
Borroni G. Critical evaluation of the variants influencing the clinical
response of vitiligo: study of 60 cases treated with ultraviolet B narrow
band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74.
doi: 10.1111/j.1468-3083.2007.02278.x.
39. Taieb A, Morice-Picard F, Jouary T, Ezzedine K, Cario^Andre M,
Gauthier Y. Segmental vitiligo as the possible expression of cutaneous
somatic mosaicism: implications for common non-segmental vitiligo.
Pigment Cell Melanoma Res. 2008; 21:646-52. doi: 10.1111/j. 1755148X.2008.00511.x.
40. Hann S, Chang J, Lee H, Kim S. The classification of segmental vitiligo
on the face. Yonsei Med J [Internet]. 2000 [ cited 2015 Oct 22]; 41(2):
209-12. Available from:http://www.ncbi.nlm.nih.gov/pubmed/10817021.
41. Bhor U, Pande S. Scoring systems in dermatology. Indian J Dermatol
Venereol Leprol [serial online] 2006 [cited 2015 Nov 10];72:315-21.
Available from: http://www.ijdvl. com/text.asp?2006/72/4/315/26722.
42. Alghamdi KM, Kumar A, Taieb A, Ezzedine K. Assessment methods for
the evaluation of vitiligo. JEADV. 2012;1-9. doi: 10.1111/j. 14683083.2012.04505.x.
43.Taieb A, Picardo M. The definition and assessment of vitiligo: a
consensus report of the Vitiligo European Task Force. Pigment Cell
Res.2007; 20:27-35. doi: 10.1111/j.1600-0749.2006.00355.
44. Kawakami T, Hashimoto T. Disease severity indexes and treatment
evaluation criteria in vitiligo. Dermatol Res Pract. 2011; 1-3. doi:
10.1155 72011/750342.
45. Al-mutairi N, Nour-Eldin O. Vitiligo treatment update. GJDV [Internet].
2003 Oct [cited 2015 Oct 23] ;10 (2): 1-13. Available from: http://www.
gulfdermaj ournal. com/pdf/2003 -10/1 .pdf.
46. Bordere AC, Lambert J, Geel NV. Current and emerging therapy for the
management of vitiligo. Clin Cosmet Investig Dermatol [Internet].
2009[cited 2015 Oct 25] ; 2: 15-25. Available from: http://www. ncbi
.nlm. nih.gov/pmc/articles/PMC3047938/.
47. Felsten L, Alikhan A, Petronic-Rosic V. Vitiligo:A comprehensive
overview part II: Treatment options and approach to treatment. J Am
Acad Dermatol [Internet]. 2011[ cited 2015 Oct 22];65:493-514.
Available from: http://www .ncbi.nlm. nih.gov/pubmed/21839316.
48. Clarke R. Lowering blood homocysteine with folic acid base
supplements: meta-analysis of randomised trials. BMJ [Internet].
1998[cited 2015 Oct 2]; 894-8. Available from:
http://www.
ncbi.nlm.nih.gov/pmc/articles/PMC28491/pdt7894.pdf.
49. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid, levels and methylenetetrahtdrofolate reductase
(MTHFR) gene polymorphism in vitiligo. Dis Markers. 2012; 33:85-9.
doi: 10.3233/DMA-2012-0908..
Universitas Sumatera Utara
55
50. Andre's E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin
AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients.
CMAJ [Internet]. 2004 [cited 2015 Oct 1] ; 17(3): 251-9. Available
from:http://www.researchgate.net/profile/Frederic_Maloisel/publicatio
n/8421627_Vitamin_B12_(cobalamin)_deficiency_in_elderly_patients
/links/OOb49 52289e7cc6179000000.pdf.
51. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bj0rke-Monsen AL,
Schneede J. Riboflavin as a determinant of plasma total homocysteine:
effect modification by the rnethylenetetrahydrofolate reductase C677T
polymorphism. Clin Chem [ Internet]. 2000 [ cited 2015 Oct 25]; May
46 (8): 1065-71. Available from: http://www .clinchem .
org/content/46/8/1065. Long.
52. Ubbink JB, Vermaak WJH, Merwe AVD, Becker PJ. Vitamin B12,vitamin b-6, and folate nutritional status in men
withhyperhomocysteinemia. Am J Clin Nutr [Internet]. 1993 [ cited
2015 Oct23] ; 57: 47-53. Availabe from: http://ajcn. nutrition,
org/ content' /57/l/47.1ong.
53. Bailey LB, Gregory JF. Folate metabolism and requirements. J. Nutr
[Internet]. 1999 [cited 2015 Oct 27]; 129: 779-82. Available from:
http://jn.nutrition.org/content/129/4/779.full.pdf+html.
54. Sabry HH, Sabry JH, Hashim HM. Serum levels of homocysteine,
vitamin B12, and folic acid in vitiligo. Egypt J Dermatol Venerol
[Internet] 2014 [cited 2015 Nov 27];34:65-9. Available from:
http://www.ejdv.eg.net/text.asp?2014/34/l/65/137315.
55. Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of
vitiligo vulgaris severity: A pilot study. J Am Acad Dermatbl. 2011.
64(2): 445-7. doi: 10.1016/j,jaad.2010.08.025.
56. Ghalamkarpour F Jafarian Z, Einollahi H, Younespour S.
Homocysteine: is it a biomarker for vitiligo? Journal of pigmentary
disorders. 2015; 2(4): 1-4. doi: 10.4172/2376-0427.1000172.
57. Yasar A, Gunduz K, Onur E, Calkan M. Serum homocysteine, vitamin
B12, folic acid levels and methylenetetrahydrofolate reductase
(MTHFR) gene polymorphism in vitiligo. Disease markers. 2012; 33:
85-9. Doi: 10.3233/DMA-2012-0908.
58. Yu H, Chang K, Yu C, Li H, Wu M, Wu C,et al. Alterations in IL-6,
IL-8, GM-CSF, TNF-a, and IFNy release by peripheral mononuclear
cells in patients
with active vitiligo.
J invest Dermatol.
1997.108: 527-9. doi: 10.111 l/1523-1747.ep12289743.
59. Becatti M, Prigano F, Fiorillo, Pescitelli L, Nassi P, Lotti T, Taddei
N.The involvement of Smac/DIABLO, p53,NF-kB, and MAPK
pathways in apoptosis of keratinocytes from perilesional vitiligft skin:
protective effects of curcumin and capsaicin. Antioxidants & Redox
Signaling. 2010; 13(9): 1309-21. doi: 10.1089/ars.2009.2779.
60. Silverberg NB. The Epidemiology of Vitiligo. Curr Derm Rep. 2015
Januari; 4:36–43.doi: 10.1007/s13671-014-0098-6.
61. Lee H. Prevalence of Vitiligo and Associated Comorbidities in Korea.
Yonsei
Med
J.
2015
Mei;
56(3):
719-25.
doi:
10.3349/ymj.2015.56.3.719.
Universitas Sumatera Utara
56
62. Jha BN. Assessment of Prevalence of Clinical and Sociodemographic
Study of Vitiligo in Janaki Medical College, Nepal. 2016
Februari;ARJLS. 2(2):1 – 4. ISSN: 2455-3549.
63. Wang X, et al. Prevalence and Clinical Profile of Vitiligo in China: A
Community based Study in Six Cities. Acta Derm Venereol 2013; 93:
62–5. doi: 10.2340/00015555-1397.
64. Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS. Gender
Differences in Clinicoepidemiological Features of Vitiligo: A CrossSectional Analysis. ISRN Dermatology. 2014 Feb;1-6. doi:
10.1155/2014/186197.
65. Zaki AM, Abdo HM, Ibrahim IM, Ibrahim AEKI. Serum homocysteine
and vitiligo. The gulf journal of dermatology and venereology[Internet].
2014[ cited 2015 Nov 29] ; 21(2): 15-20. Availble from: https://www.
google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0ah
UKEwjzy8p1cnKAhVBBY4KHQnjB1EQFggrMAI&url=http%3A%2F
%2Fwww.gulfdermajournal.com%2Fpdf%2F201410%2F2.pdf&usg=AF
QjCNGXyvhhvl6trAe0SHRVAImXn0Yi1g&sig2=5MUvJNMVGIU_eS
1rBkBO7A&cad=rj
66. Koehler KM, Baum RG, Gary PJ, Allen RH, Stabler SP, Rimm EB.
Association of folate intake and serum homocysteine in elderly persons
according to vitamin supplementation and alcohol use. Am J Clin Nutr.
2001 March ; 73:628–37. PMID:11237942.
67. Agarwal S, Mendiratta V, Chander R, Jain A, Yadav P. Study of serum
levels of Vitamin B, folic acid, and homocysteine in vitiligo. Pigment Int
2015;2:76-80. doi: 10.4103/2349-5847.172777
Universitas Sumatera Utara